Licensor	Technology	Field	Exclusivity	Licensee	Announcement	Business data	Expected update - Expiry
Massachusetts General Hospital (MGH)	IP and technology related to high-fidelity Cas9 nucleases and Cas9 PAM variants	to develop new therapies for an expanded range of genetic diseases	Exclusive	Editas Medicine	2016/08		
Broad MIT Harvard, Harvard, MIT, Wageningen university,Uni Iowa, Uni Tokyo	IP for the new CRISPR genome editing system known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.	for human therapeutics that will enhance and broaden the range of medicines	Exclusive for two years	Editas Medicine	2016/12	Editas Medicine will make total upfront cash payments of $6.25 million and issue a promissory note totaling $10 million that can be settled in stock or cash over a predefined period. In the future, Editas Medicine may make additional payments, in cash or stock upon reaching goals and targets related to research and development, commercialization, and market capitalization, and will pay royalties on products based on these technologies. In addition, these licenses employ the inclusive innovation model developed by Broad Institute, Harvard University, and MIT, which is designed to maximize the opportunity for groundbreaking innovations to reach the largest number of patients.	2018/12
Editas Medicine	up to five of Editas's early-stage CRISPR genome-editing programs targeting eye diseases, including its lead preclinical program for Leber congenital amaurosis (LCA10)	Exclusive access and a licensing option to up to five of Editas's early-stage CRISPR genome-editing programs targeting eye diseases, including its lead preclinical program for Leber congenital amaurosis (LCA10)	Exclusive access ad licensing option	Allergan	2017/03		
MIT	Lipid Nanoparticles technologies	in vivo CRISR-Cas9 based theraoies. Primary focus on liver applications	Exclusive	CRISPR Therapeutics	2017/05		
ERS Genomics	ERS patent portfolio covering CRISPR-Cas genome editing technology	for all agricultural uses and applications in plants	Exclusive	Dupont	2017/06		
Seattle Children's Research Institute	CRISPR/Cas9 gene-edited regulatory T cells (Tregs)	to explore new methods to treat and prevent autoimmune disease using CRISPR/Cas9 gene-edited regulatory T cells (Tregs)	Exclusive worldwide rights to develop and commercialize specific intellectual property related to the collaboration.	Casebia Therapeutics	2017/09	Over the course of the collaboration agreement, funding contributions to Seattle Children's could exceed $12 million.	
Duke University	IP and techonology related to CRISPR-Cas9	Duchenne muscular dystrophy (DMD) therapy	Exclusive	Sarepta	2017/10	Research and option agreement	